Home Cart Sign in  
Chemical Structure| 21499-66-1 Chemical Structure| 21499-66-1

Structure of Bruceine D
CAS No.: 21499-66-1

Chemical Structure| 21499-66-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Bruceine D is a Notch inhibitor with anticancer activity, inducing apoptosis in several human cancer cell lines. Bruceine D shows potent insecticidal activity with an EC50 value of 0.57 mg/L against D. intermedius.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Bruceine D

CAS No. :21499-66-1
Formula : C20H26O9
M.W : 410.42
SMILES Code : O=C1[C@H](O)[C@]2(O)[C@@]34[C@@]([C@@H](O)[C@H](O)[C@@]2(C)OC4)([H])[C@]5(C)[C@@](C(C)=CC([C@H]5O)=O)([H])C[C@@]3([H])O1
MDL No. :MFCD00221753

Safety of Bruceine D

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
MDA-MB-453 3.13–25 μM 48 h BD inhibited MDA-MB-453 cell viability with an IC50 of 9.919 μM. J Adv Res. 2024 Apr;58:193-210
MCF-7 0.78–25 μM 48 h BD inhibited MCF-7 cell viability with an IC50 of 2.805 μM. J Adv Res. 2024 Apr;58:193-210
MDA-MB-231 0.78–25 μM 48 h BD inhibited MDA-MB-231 cell viability with an IC50 of 2.328 μM. J Adv Res. 2024 Apr;58:193-210
MDA-MB-468 0.39–25 μM 48 h BD inhibited MDA-MB-468 cell viability with an IC50 of 1.092 μM. J Adv Res. 2024 Apr;58:193-210
SGC7901 cells 1.2 μM 2 weeks BD significantly inhibited the clonogenicity of SGC7901 cells. Front Pharmacol. 2020 Nov 24;11:584960
NCI-H292 2.5, 5, 10, 20, 30, and 40 µM 24 h and 48 h BD inhibited human lung cancer cell growth in a dose- and time-dependent manner. The IC50 (24 h) values for A549 and NCI-H292 cells were 36.76 and 31.22 μM, respectively, and the IC50 (48 h) values were 17.89 and 14.42 μM, respectively. Cell Death Dis. 2020 Feb 18;11(2):126
A549 cells 2.5, 5, 10, 20, 30, and 40 µM 24 h and 48 h BD inhibited human lung cancer cell growth in a dose- and time-dependent manner. The IC50 (24 h) values for A549 and NCI-H292 cells were 36.76 and 31.22 μM, respectively, and the IC50 (48 h) values were 17.89 and 14.42 μM, respectively. Cell Death Dis. 2020 Feb 18;11(2):126
A549 cells 0.05, 0.5, 1, 5, 25, 50 µg/ml 24, 48, 72 h Evaluate the effect of Bruceine D on the proliferation of A549 cells, results showed that Bruceine D significantly inhibited the proliferation of A549 cells, with an IC50 value of 1.01±0.11 µg/ml Int J Mol Med. 2019 Dec;44(6):2015-2026
MCF-10A 3.13–25 μM 48 h BD inhibited MCF-10A cell viability with an IC50 of 12.200 μM. J Adv Res. 2024 Apr;58:193-210
PANC-1 0.5-1.5 μM 24-48 h To evaluate the inhibitory effect of BD on PDAC cell proliferation and its enhancement of GEM chemosensitivity. Results showed that BD significantly inhibited PDAC cell proliferation and enhanced GEM chemosensitivity by downregulating the Nrf2 pathway. J Exp Clin Cancer Res. 2022 Mar 10;41(1):90
Capan-2 0.5-1.5 μM 24-48 h To evaluate the inhibitory effect of BD on PDAC cell proliferation and its enhancement of GEM chemosensitivity. Results showed that BD significantly inhibited PDAC cell proliferation and enhanced GEM chemosensitivity by downregulating the Nrf2 pathway. J Exp Clin Cancer Res. 2022 Mar 10;41(1):90
Miapaca-2 0.5-1.5 μM 24-48 h To evaluate the inhibitory effect of BD on PDAC cell proliferation and its enhancement of GEM chemosensitivity. Results showed that BD significantly inhibited PDAC cell proliferation and enhanced GEM chemosensitivity by downregulating the Nrf2 pathway. J Exp Clin Cancer Res. 2022 Mar 10;41(1):90
BT474 3.13–25 μM 48 h BD inhibited BT474 cell viability with an IC50 of 12.100 μM. J Adv Res. 2024 Apr;58:193-210
Huh7 cells 1.89 μM (IC50) 48 h To evaluate the inhibitory effect of BD on Huh7 cell proliferation under hypoxic conditions. Results showed that BD dose-dependently inhibited Huh7 cell viability. Acta Pharm Sin B. 2021 Nov;11(11):3481-3492
HepG2 cells 8.34 μM (IC50) 48 h To evaluate the inhibitory effect of BD on HepG2 cell proliferation under hypoxic conditions. Results showed that BD dose-dependently inhibited HepG2 cell viability. Acta Pharm Sin B. 2021 Nov;11(11):3481-3492

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c-nu mice Lung cancer xenograft model Intraperitoneal injection 40 mg/kg Every 2 days for 15 days BD significantly reduced the growth of xenograft tumors without significant changes in body weight. An increase in the number of TUNEL-positive cells and upregulation of LC3-II, cleaved caspase-9, p-ERK and p-JNK were observed following BD treatment. H&E staining results suggested that BD exhibited no significant toxicity in vivo. Cell Death Dis. 2020 Feb 18;11(2):126
BALB/c nude mice Xenograft model of gastric cancer cells SGC7901 and MKN45 Intraperitoneal injection 1.5 mg/kg Every two days for 14 days BD significantly inhibited tumor growth and reduced tumor weight in gastric cancer cells. Front Pharmacol. 2020 Nov 24;11:584960
BALB/c nude mice Orthotopic xenograft and genetically engineered KPC mouse models of PDAC Oral gavage 2 mg/kg Once daily for 4 weeks To evaluate the inhibitory effect of BD alone or in combination with GEM on PDAC tumor growth. Results showed that BD significantly inhibited tumor growth and enhanced GEM chemosensitivity by inhibiting the Nrf2 pathway. J Exp Clin Cancer Res. 2022 Mar 10;41(1):90
NCG mice MDA-MB-231 xenograft model Intraperitoneal injection 2.5 mg/kg Daily for 21 days BD significantly inhibited tumor growth in the Trop2-OE group with an inhibition rate of 70.81%. J Adv Res. 2024 Apr;58:193-210
BALB/c nude mice Huh7 xenograft model Tail vein injection 0.75 and 1.5 mg/kg Once daily for 14 days To evaluate the anti-tumor activity of BD in the Huh7 xenograft model. Results showed that BD at 1.5 mg/kg/day significantly inhibited tumor growth without significant body weight loss or side effects. Acta Pharm Sin B. 2021 Nov;11(11):3481-3492

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.44mL

0.49mL

0.24mL

12.18mL

2.44mL

1.22mL

24.37mL

4.87mL

2.44mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories